Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?

Lorrin M. Koran, John W. Cain, Roberto A. Dominguez, A. John Rush, Sue Thiemann

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective: In obsessive-compulsive disorder, the relationship between blood levels of serotonin reuptake inhibitors and clinical outcome is unclear. In a multicenter trial, the authors examined the relationship between steady state plasma levels of fluoxetine and norfluoxetine (determined after 7 weeks of treatment), and their sum, and clinical outcome. Method: Ratings of symptom severity of obsessive-compulsive disorder (Yale- Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive- compulsive disorder treated with fluoxetine doses of 20 mg/day (N=68), 40 mg/day (N=64), and 60 mg/day (N=68). Results: Mean plasma levels of fluoxetine and norfluoxetine were statistically significantly higher with higher dose. Statistical analyses revealed no significant relationship for plasma level of either molecule or their sum in predicting endpoint percent change in obsessive-compulsive scores. Plasma levels of patients with a marked response (decrease of 50% or more in obsessive-compulsive score) did not differ significantly from those of nonresponders (less than a 25% decrease in obsessive-compulsive score). No hint was seen of a therapeutic window or of a relationship limited to one gender or within the lowest dose group (20 mg/day). However, since S-norfluoxetine is a much more potent serotonin reuptake inhibitor than R-norfluoxetine, the absence of chiral (stereospecific) assays in this study limits the results. Conclusions: Steady state plasma levels of fluoxetine and norfluoxetine are not related to clinical outcome in patients with obsessive-compulsive disorder. Individual patients can be told only that the optimum dose of fluoxetine for them will be the dose that produces the largest therapeutic effect with the smallest side effect burden. Future studies should examine the predictive utility of measures of serotonergic neuronal function and, if plasma levels of norfluoxetine are examined, the use of chiral assays.

Original languageEnglish (US)
Pages (from-to)1450-1454
Number of pages5
JournalAmerican Journal of Psychiatry
Volume153
Issue number11
StatePublished - Nov 1996

Fingerprint

Fluoxetine
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Therapeutic Uses
Multicenter Studies
norfluoxetine
Outpatients
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Koran, L. M., Cain, J. W., Dominguez, R. A., Rush, A. J., & Thiemann, S. (1996). Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? American Journal of Psychiatry, 153(11), 1450-1454.

Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? / Koran, Lorrin M.; Cain, John W.; Dominguez, Roberto A.; Rush, A. John; Thiemann, Sue.

In: American Journal of Psychiatry, Vol. 153, No. 11, 11.1996, p. 1450-1454.

Research output: Contribution to journalArticle

Koran, LM, Cain, JW, Dominguez, RA, Rush, AJ & Thiemann, S 1996, 'Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?', American Journal of Psychiatry, vol. 153, no. 11, pp. 1450-1454.
Koran, Lorrin M. ; Cain, John W. ; Dominguez, Roberto A. ; Rush, A. John ; Thiemann, Sue. / Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?. In: American Journal of Psychiatry. 1996 ; Vol. 153, No. 11. pp. 1450-1454.
@article{aed4a9203e844c9dbe2adbd786928712,
title = "Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?",
abstract = "Objective: In obsessive-compulsive disorder, the relationship between blood levels of serotonin reuptake inhibitors and clinical outcome is unclear. In a multicenter trial, the authors examined the relationship between steady state plasma levels of fluoxetine and norfluoxetine (determined after 7 weeks of treatment), and their sum, and clinical outcome. Method: Ratings of symptom severity of obsessive-compulsive disorder (Yale- Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive- compulsive disorder treated with fluoxetine doses of 20 mg/day (N=68), 40 mg/day (N=64), and 60 mg/day (N=68). Results: Mean plasma levels of fluoxetine and norfluoxetine were statistically significantly higher with higher dose. Statistical analyses revealed no significant relationship for plasma level of either molecule or their sum in predicting endpoint percent change in obsessive-compulsive scores. Plasma levels of patients with a marked response (decrease of 50{\%} or more in obsessive-compulsive score) did not differ significantly from those of nonresponders (less than a 25{\%} decrease in obsessive-compulsive score). No hint was seen of a therapeutic window or of a relationship limited to one gender or within the lowest dose group (20 mg/day). However, since S-norfluoxetine is a much more potent serotonin reuptake inhibitor than R-norfluoxetine, the absence of chiral (stereospecific) assays in this study limits the results. Conclusions: Steady state plasma levels of fluoxetine and norfluoxetine are not related to clinical outcome in patients with obsessive-compulsive disorder. Individual patients can be told only that the optimum dose of fluoxetine for them will be the dose that produces the largest therapeutic effect with the smallest side effect burden. Future studies should examine the predictive utility of measures of serotonergic neuronal function and, if plasma levels of norfluoxetine are examined, the use of chiral assays.",
author = "Koran, {Lorrin M.} and Cain, {John W.} and Dominguez, {Roberto A.} and Rush, {A. John} and Sue Thiemann",
year = "1996",
month = "11",
language = "English (US)",
volume = "153",
pages = "1450--1454",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "11",

}

TY - JOUR

T1 - Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?

AU - Koran, Lorrin M.

AU - Cain, John W.

AU - Dominguez, Roberto A.

AU - Rush, A. John

AU - Thiemann, Sue

PY - 1996/11

Y1 - 1996/11

N2 - Objective: In obsessive-compulsive disorder, the relationship between blood levels of serotonin reuptake inhibitors and clinical outcome is unclear. In a multicenter trial, the authors examined the relationship between steady state plasma levels of fluoxetine and norfluoxetine (determined after 7 weeks of treatment), and their sum, and clinical outcome. Method: Ratings of symptom severity of obsessive-compulsive disorder (Yale- Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive- compulsive disorder treated with fluoxetine doses of 20 mg/day (N=68), 40 mg/day (N=64), and 60 mg/day (N=68). Results: Mean plasma levels of fluoxetine and norfluoxetine were statistically significantly higher with higher dose. Statistical analyses revealed no significant relationship for plasma level of either molecule or their sum in predicting endpoint percent change in obsessive-compulsive scores. Plasma levels of patients with a marked response (decrease of 50% or more in obsessive-compulsive score) did not differ significantly from those of nonresponders (less than a 25% decrease in obsessive-compulsive score). No hint was seen of a therapeutic window or of a relationship limited to one gender or within the lowest dose group (20 mg/day). However, since S-norfluoxetine is a much more potent serotonin reuptake inhibitor than R-norfluoxetine, the absence of chiral (stereospecific) assays in this study limits the results. Conclusions: Steady state plasma levels of fluoxetine and norfluoxetine are not related to clinical outcome in patients with obsessive-compulsive disorder. Individual patients can be told only that the optimum dose of fluoxetine for them will be the dose that produces the largest therapeutic effect with the smallest side effect burden. Future studies should examine the predictive utility of measures of serotonergic neuronal function and, if plasma levels of norfluoxetine are examined, the use of chiral assays.

AB - Objective: In obsessive-compulsive disorder, the relationship between blood levels of serotonin reuptake inhibitors and clinical outcome is unclear. In a multicenter trial, the authors examined the relationship between steady state plasma levels of fluoxetine and norfluoxetine (determined after 7 weeks of treatment), and their sum, and clinical outcome. Method: Ratings of symptom severity of obsessive-compulsive disorder (Yale- Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive- compulsive disorder treated with fluoxetine doses of 20 mg/day (N=68), 40 mg/day (N=64), and 60 mg/day (N=68). Results: Mean plasma levels of fluoxetine and norfluoxetine were statistically significantly higher with higher dose. Statistical analyses revealed no significant relationship for plasma level of either molecule or their sum in predicting endpoint percent change in obsessive-compulsive scores. Plasma levels of patients with a marked response (decrease of 50% or more in obsessive-compulsive score) did not differ significantly from those of nonresponders (less than a 25% decrease in obsessive-compulsive score). No hint was seen of a therapeutic window or of a relationship limited to one gender or within the lowest dose group (20 mg/day). However, since S-norfluoxetine is a much more potent serotonin reuptake inhibitor than R-norfluoxetine, the absence of chiral (stereospecific) assays in this study limits the results. Conclusions: Steady state plasma levels of fluoxetine and norfluoxetine are not related to clinical outcome in patients with obsessive-compulsive disorder. Individual patients can be told only that the optimum dose of fluoxetine for them will be the dose that produces the largest therapeutic effect with the smallest side effect burden. Future studies should examine the predictive utility of measures of serotonergic neuronal function and, if plasma levels of norfluoxetine are examined, the use of chiral assays.

UR - http://www.scopus.com/inward/record.url?scp=0029858120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029858120&partnerID=8YFLogxK

M3 - Article

VL - 153

SP - 1450

EP - 1454

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 11

ER -